Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339064 · ClinicalTrials.gov registry record · Phase 3
Infusion of Apomorphine: Long-term Safety Study
A Phase 3 study of Idiopathic Parkinson´s Disease, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
- 18
- Study locations
NCT02339064: Active Phase 3 study of Idiopathic Parkinson´s Disease, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.
NCT02339064 is a Phase 3 study of Idiopathic Parkinson´s Disease that is active but no longer recruiting, run by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals. The registered enrollment target is 99 participants, below the 206-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (52% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02339064, a Phase 3 study of Idiopathic Parkinson´s Disease, is active but no longer recruiting, sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.
Conditions Studied
Interventions
- DRUG apomorphine infusion
Study Locations (18)
California
- - Loma Linda
- - Los Angeles
- - Los Angeles
Colorado
- - Aurora
- - Englewood
Georgia
- - Atlanta
- - Augusta
Illinois
- - Chicago
- - Chicago
Arizona
- - Phoenix
Florida
- - Boca Raton
Kansas
- - Kansas City
Michigan
- - West Bloomfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2015-02 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
What the registry record for NCT02339064 still lists
NCT02339064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 206-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Idiopathic Parkinson´s Disease appearing as the primary indexed condition, and to 1 intervention - of which apomorphine infusion is the first listed.
NCT02339064 lists 18 locations in 13 states (California, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT02339064 about?
NCT02339064 is a clinical study titled "Infusion of Apomorphine: Long-term Safety Study". This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therap...
What is the current status of trial NCT02339064?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2015-02. Estimated completion is 2025-12.
What conditions does trial NCT02339064 study?
This clinical trial studies the following conditions: Idiopathic Parkinson´s Disease.
What interventions are being tested in trial NCT02339064?
The interventions under investigation include: apomorphine infusion (DRUG).
Who is sponsoring clinical trial NCT02339064?
This trial is sponsored by MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02339064 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Parkinson´s Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
COMPLETED · Phase 3
-
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
COMPLETED · Phase 3
-
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
COMPLETED · Phase 3
-
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
RECRUITING · Phase 1
-
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
COMPLETED · Phase 2
-
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia